Cargando…
Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-κB signaling
BACKGROUND: According to GLOBOSCAN, hepatocellular carcinoma (HCC) claimed 782,000 lives in 2018. The tyrosine kinase inhibitor sofafenib is used to treat HCC, but new anticancer agents targeting different pathways are urgently needed to improve outcomes for patients with advanced disease. The aberr...
Autores principales: | Soong, Ruey-Shyang, Anchoori, Ravi K., Roden, Richard B. S., Cho, Rou-Ling, Chen, Yi-Chan, Tseng, Sheng-Chieh, Huang, Yun-Li, Liao, Po-Cheng, Shyu, Yu-Chiau |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201939/ https://www.ncbi.nlm.nih.gov/pubmed/32375699 http://dx.doi.org/10.1186/s12885-020-06896-0 |
Ejemplares similares
-
RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells
por: Soong, Ruey-Shyang, et al.
Publicado: (2016) -
Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties
por: Anchoori, Ravi K., et al.
Publicado: (2020) -
Covalent Rpn13-Binding Inhibitors for
the Treatment of Ovarian Cancer
por: Anchoori, Ravi K., et al.
Publicado: (2018) -
Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor
por: Anchoori, Ravi K., et al.
Publicado: (2023) -
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors
por: Anchoori, Ravi K., et al.
Publicado: (2021)